Literature DB >> 28619255

Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents.

Oyekoya T Ayonrinde1, Wendy H Oddy2, Leon A Adams3, Trevor A Mori4, Lawrence J Beilin4, Nicholas de Klerk5, John K Olynyk6.   

Abstract

BACKGROUND & AIMS: The pathway to non-alcoholic fatty liver disease (NAFLD) in adolescents may have its origins in adiposity gains, nutrition and sedentary lifestyle established during childhood. There is inadequate knowledge regarding the associations between infant nutrition and subsequent NAFLD. We examined the association of maternal factors and infant nutrition, with the subsequent diagnosis of NAFLD in adolescents.
METHODS: Adolescents aged 17years in the Western Australian Pregnancy (Raine) Cohort study had fatty liver assessment using liver ultrasound. Prospectively recorded data on maternal pregnancy and infant feeding were examined against a NAFLD outcome during late adolescence.
RESULTS: NAFLD was diagnosed in 15.2% of the 1,170 adolescents examined. Ninety-four percent had been breastfed as infants. The duration of breastfeeding before starting supplementary milk was ⩾4months in 54.4% and ⩾6months in 40.6%. Breastfeeding without supplementary milk ⩾6months (adjusted odds ratio [OR]: 0.64; 95% confidence interval [CI]: 0.43-0.94, p=0.02), maternal pre-pregnancy obesity (adjusted OR: 2.29; 95% CI: 1.21-4.32, p=0.01) and adolescent obesity (adjusted OR: 9.08; 95% CI: 6.26-13.17, p<0.001) were associated with NAFLD independent of a Western dietary pattern at 17years of age. Adolescents with NAFLD who had been breastfed for ⩾6months had a less adverse metabolic profile compared with adolescents breastfed for <6months. Supplementary milk intake starting before 6months was associated with a higher prevalence and ultrasound severity of NAFLD compared with intake starting after 6months (17.7% vs. 11.2%, p=0.003 and 7.8% vs. 3.4%, p=0.005 respectively).
CONCLUSION: Though NAFLD is generally mediated through adiposity gains, breastfeeding for at least 6months, avoidance of early supplementary formula milk feeding, and normal maternal pre-pregnancy BMI may reduce the odds of a NAFLD diagnosis during adolescence. LAY
SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder in which there is too much fat in the liver of people who do not consume excessive amounts of alcohol. In this large study, we found that infants who consumed breast milk for less than 6months before starting infant formula milk, infants who were obese as teenagers or had mothers who were obese at the start of pregnancy, were much more likely to have NAFLD at 17years of age. Based on our findings we consider that reducing the risk of NAFLD in teenagers needs to start before birth, by encouraging normal body mass index before pregnancy, as well as breastfeeding without infant formula milk consumption for the first 6months of life. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adolescents; Breastfeeding; Complementary feeding; Formula milk; Infant feeding; Maternal obesity; Non-alcoholic fatty liver disease; Obesity; Pregnancy; Raine study; Risk factors; Supplementary milk

Mesh:

Year:  2017        PMID: 28619255     DOI: 10.1016/j.jhep.2017.03.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

1.  Perinatal programming of adolescent nonalcoholic fatty liver disease: A case for gender inequality?

Authors:  Monika Sarkar; Gyorgy Baffy
Journal:  Hepatology       Date:  2017-11-13       Impact factor: 17.425

2.  Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women.

Authors:  Veeral H Ajmera; Norah A Terrault; Lisa B VanWagner; Monika Sarkar; Cora E Lewis; John J Carr; Erica P Gunderson
Journal:  J Hepatol       Date:  2018-11-01       Impact factor: 25.083

3.  Associations of Early to Mid-Childhood Adiposity with Elevated Mid-Childhood Alanine Aminotransferase Levels in the Project Viva Cohort.

Authors:  Jennifer A Woo Baidal; Erin E Elbel; Joel E Lavine; Sheryl L Rifas-Shiman; Matthew W Gillman; Emily Oken; Elsie M Taveras
Journal:  J Pediatr       Date:  2018-04-04       Impact factor: 4.406

Review 4.  Measuring growth and medium- and longer-term outcomes in malnourished children.

Authors:  Victor O Owino; Alexia J Murphy-Alford; Marko Kerac; Paluku Bahwere; Henrik Friis; James A Berkley; Alan A Jackson
Journal:  Matern Child Nutr       Date:  2019-02-27       Impact factor: 3.092

5.  Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes.

Authors:  Melissa Hershman; Rena Mei; Tatyana Kushner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-04

6.  Nonalcoholic Fatty Liver Disease in Children.

Authors:  Katherine F Sweeny; Christine K Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-12

7.  Maternal obesogenic diet regulates offspring bile acid homeostasis and hepatic lipid metabolism via the gut microbiome in mice.

Authors:  Michael D Thompson; Jisue Kang; Austin Faerber; Holly Hinrichs; Oğuz Özler; Jamie Cowen; Yan Xie; Phillip I Tarr; Nicholas O Davidson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-01-05       Impact factor: 4.052

Review 8.  Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  J Clin Exp Hepatol       Date:  2019-05-31

9.  Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy.

Authors:  Shuguang Han; Feng Zhu; Xiaoxia Huang; Panpan Yan; Ke Xu; Fangfang Shen; Jiawen Sun; Zeyu Yang; Guoxi Jin; Yiqun Teng
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

10.  Effects of maternal taurine supplementation on maternal dietary intake, plasma metabolites and fetal growth and development in cafeteria diet fed rats.

Authors:  Arzu Kabasakal Çetin; Tuǧba Alkan Tuğ; Atila Güleç; Aslı Akyol
Journal:  PeerJ       Date:  2021-06-03       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.